SAN DIEGO, CA - April 3, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC:QTZM), a pioneering biotechnology company specializing in computational enzyme engineering, announced today that it will become a fully reporting company with the U.S. Securities & Exchange Commission (SEC) on April 4, 2025, following the automatic effectiveness of its Form 10 registration statement filed on February 3, 2025.
Under Section 12(g) of the Securities Exchange Act of 1934, a Form 10 becomes effective 60 days after filing. This transition to fully reporting status marks a key regulatory and strategic milestone for Quantumzyme, as it strengthens transparency, expands access to capital markets, and positions the company for long-term growth.
“Becoming a fully reporting issuer is a transformative step forward for Quantumzyme,” stated Naveen Kulkarni, CEO of Quantumzyme. “It signifies our commitment to the highest standards of transparency, accountability, and investor confidence. This milestone not only enhances our credibility, but also unlocks access to the broader public capital markets that fuel innovation and scale.”
“With this new status, we’re better positioned to attract long-term institutional capital, form high-impact strategic partnerships, and potentially uplist in the future,” added Kulkarni. “We see this as a launchpad to accelerate our mission of delivering powerful enzymatic technologies that reshape industries and improve lives.”
The company’s reporting obligations will now include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, providing consistent and comprehensive insight into its operations and performance.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services—from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
